股本结构
单位：万股
| 公告日期 | 2024-04-16 | 2023-08-09 | 2023-05-25 | 2023-05-12 | 2023-03-23 | 2022-03-24 |
|---|---|---|---|---|---|---|
| 证券总股本 | 311.92 | 311.67 | 311.68 | 3116.84 | 3116.84 | 4025.49 |
| 普通股本 | 311.92 | 311.67 | 311.68 | 3116.84 | 3116.84 | 4025.49 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-04-15 | 2023-06-30 | 2023-05-26 | 2023-03-31 | 2023-03-16 | 2021-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-16 | 311.92 | 未披露 | 定期报告 | 2024-04-15 |
| 2023-08-09 | 311.67 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Fractional shares adjustment due to reverse stock split
|
2023-06-30 |
| 2023-05-25 | 311.68 | 未披露 |
更多>>
Landos Biopharma, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time, May 25, 2023.
|
2023-05-26 |
| 2023-05-12 | 3116.84 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Repurchase and retirement of common stock
|
2023-03-31 |
| 2023-03-23 | 3116.84 | 未披露 | 定期报告 | 2023-03-16 |
| 2022-03-24 | 4025.49 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Conversion of preferred stock to common stock upon closing of initial public offering
Issuance of common stock, net of issuance costs
Exercise of stock options
|
2021-12-31 |
| 2021-11-15 | 4023.57 | 未披露 | 定期报告 | 2021-11-14 |
| 2021-11-15 | 4005.32 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of stock options
|
2021-09-30 |
| 2021-07-29 | 4011.76 | 未披露 | 定期报告 | 2021-07-29 |
| 2021-07-29 | 3990.09 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Conversion of preferred stock to common stock upon closing of the initial public offering
|
2021-06-30 |
| 2021-05-17 | 4011.76 | 未披露 | 定期报告 | 2021-05-17 |
| 2021-05-17 | 3986.67 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Conversion of preferred stock to common stock upon closing of the initial public offering
Issuance of common stock, net of issuance costs
Exercise of Stock Options
|
2021-03-31 |
| 2021-03-31 | 4011.76 | 未披露 | 定期报告 | 2021-03-29 |
| 2021-02-04 | 3916.32 | 未披露 |
更多>>
1.Common stock offered by the company 6,250,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 32,913,174 shares of common stock (including preferred stock on an as-converted basis) outstanding as of September 30, 2020
|
2021-02-04 |
From March 31, 2023 to June 30, 2023
Fractional shares adjustment due to reverse stock split
Landos Biopharma, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time, May 25, 2023.
From December 31, 2022 to March 31, 2023
Repurchase and retirement of common stock
From December 31, 2020 to December 31, 2021
Conversion of preferred stock to common stock upon closing of initial public offering
Issuance of common stock, net of issuance costs
Exercise of stock options
From June 30, 2021 to September 30, 2021
Exercise of stock options
From March 31, 2021 to June 30, 2021
Conversion of preferred stock to common stock upon closing of the initial public offering
From December 31, 2020 to March 31, 2021
Conversion of preferred stock to common stock upon closing of the initial public offering
Issuance of common stock, net of issuance costs
Exercise of Stock Options
1.Common stock offered by the company 6,250,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 32,913,174 shares of common stock (including preferred stock on an as-converted basis) outstanding as of September 30, 2020